Reply to A. Okeya et al

Abstract

We thank Okeya et al 1 for their interest in and valuable comments on our recently published article 2 reporting the primary analysis of the phase II acelERA Breast Cancer (BC) study (ClinicalTrials.gov identifier: NCT04576455).